| Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma (NCT04792502) | Brown University | 2022-07-14 |
| Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma (NCT05296070) | University of Miami | 2022-06-21 |
| Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (NCT05294731) | BeiGene | 2022-05-06 |
| Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma (NCT05326308) | iOMEDICO AG | 2022-04-26 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia (NCT05281809) | John Lister | 2022-04-19 |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (NCT05169658) | University of Washington | 2022-03-23 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (NCT05100862) | BeOne Medicines | 2022-03-10 |
| Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (NCT04268277) | University of Ulm | 2022-03-01 |
| Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells (NCT04911478) | Adicet Therapeutics | 2022-02-14 |
| Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies (NCT04599634) | National Cancer Institute (NCI) | 2021-12-16 |
| PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies (NCT05003141) | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | 2021-11-15 |
| Study of Acalabrutinib and Tafasitamab in MZL Patients (NCT04646395) | International Extranodal Lymphoma Study Group (IELSG) | 2021-10-20 |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (NCT05006716) | BeOne Medicines | 2021-09-13 |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas (NCT04883437) | Emory University | 2021-09-03 |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) (NCT04745832) | MEI Pharma, Inc. | 2021-08-13 |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (NCT04491370) | New York Medical College | 2021-08-01 |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. (NCT04775745) | Newave Pharmaceutical Inc | 2021-07-19 |
| A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (NCT04669171) | Enterome | 2021-07-05 |
| A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma (NCT04416451) | Memorial Sloan Kettering Cancer Center | 2021-05-04 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT04806035) | TG Therapeutics, Inc. | 2021-04-28 |
| A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (NCT04680052) | Incyte Corporation | 2021-04-15 |
| Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma (NCT04849351) | Hutchison Medipharma Limited | 2021-04-15 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| A Phase 1 Study of ADI-001 in B Cell Malignancies (NCT04735471) | Adicet Therapeutics | 2021-03-04 |
| FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role (NCT04333524) | International Extranodal Lymphoma Study Group (IELSG) | 2020-12-01 |
| Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) (NCT04665115) | Academic and Community Cancer Research United | 2020-11-23 |
| Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma (NCT04508647) | University of Colorado, Denver | 2020-11-23 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (NCT04072458) | Bio-Path Holdings, Inc. | 2020-11-05 |
| Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma (NCT04189952) | University of Miami | 2020-09-22 |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (NCT04542824) | Genmab | 2020-08-20 |
| 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers (NCT04464200) | Memorial Sloan Kettering Cancer Center | 2020-07-06 |
| A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies (NCT04279405) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-06-15 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520) | Medical College of Wisconsin | 2020-05-18 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (NCT04282018) | BeiGene | 2020-04-29 |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) (NCT04018248) | Boryung Pharmaceutical Co., Ltd | 2020-04-21 |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies (NCT04043845) | Dana-Farber Cancer Institute | 2020-02-03 |
| A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma (NCT04212013) | Memorial Sloan Kettering Cancer Center | 2019-12-23 |
| Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (NCT03474744) | Christian Buske | 2019-12-15 |
| Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (NCT04116437) | BeiGene | 2019-10-15 |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (NCT04082936) | IGM Biosciences, Inc. | 2019-09-30 |
| MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (NCT03697512) | International Extranodal Lymphoma Study Group (IELSG) | 2019-09-27 |
| Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma (NCT03919175) | Massachusetts General Hospital | 2019-09-01 |
| Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) (NCT03768505) | MEI Pharma, Inc. | 2019-06-25 |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (NCT03740529) | Loxo Oncology, Inc. | 2019-03-15 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) (NCT03833180) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2019-03-14 |
| Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma (NCT03884998) | City of Hope Medical Center | 2019-02-26 |
| Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma (NCT03846427) | BeiGene | 2019-02-19 |
| Obinutuzumab in Marginal Zone Lymphoma (NCT03322865) | Christian Buske | 2018-11-23 |
| Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors (NCT03010982) | Epizyme, Inc. | 2018-06-20 |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT03410901) | Ronald Levy | 2018-04-09 |
| Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas (NCT03276468) | The Lymphoma Academic Research Organisation | 2018-02-12 |
| BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) (NCT03520920) | BeiGene | 2018-01-04 |
| A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (NCT03088878) | Oncternal Therapeutics, Inc | 2018-01-03 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma (NCT03364231) | TG Therapeutics, Inc. | 2017-11-30 |
| 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation (NCT03133221) | University of Maryland, Baltimore | 2017-10-23 |
| A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma (NCT03078855) | Jonathan Friedberg | 2017-09-07 |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (NCT02952508) | Cellectar Biosciences, Inc. | 2017-07-26 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (NCT03010358) | Alexey Danilov, MD | 2017-07-17 |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (NCT03162536) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2017-06-26 |
| A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (NCT03105336) | Kite, A Gilead Company | 2017-06-06 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers (NCT03037645) | Sunesis Pharmaceuticals | 2017-04-28 |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients (NCT03028103) | Epizyme, Inc. | 2017-03-27 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773) | University of Arizona | 2016-11-29 |
| TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma (NCT02927964) | Robert Lowsky | 2016-11-07 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (NCT02793583) | TG Therapeutics, Inc. | 2016-05-25 |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (NCT02339922) | University of Washington | 2016-05-19 |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02623920) | University of Arizona | 2015-12-16 |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) (NCT02576275) | SecuraBio | 2015-12-01 |
| Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma (NCT02258555) | Gilead Sciences | 2015-01-01 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) (NCT02242045) | Gilead Sciences | 2014-10-01 |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma (NCT01980628) | Pharmacyclics LLC. | 2013-12-01 |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL (NCT01728207) | Gilead Sciences | 2013-03-01 |
| Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies (NCT01744912) | TG Therapeutics, Inc. | 2012-11-21 |
| A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) (NCT01500538) | Peter MacCallum Cancer Centre, Australia | 2012-10-01 |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT01647971) | TG Therapeutics, Inc. | 2012-07-19 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies (NCT01474681) | Novartis Pharmaceuticals | 2012-01-09 |
| Imexon for Relapsed Follicular and Aggressive Lymphomas (NCT01314014) | University of Rochester | 2011-05-01 |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (NCT01282424) | Gilead Sciences | 2011-03-18 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (NCT01484015) | Wake Forest University Health Sciences | 2011-02-01 |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma (NCT01306643) | Gilead Sciences | 2011-02-01 |
| Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma (NCT01239394) | Massachusetts General Hospital | 2010-12-01 |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01239875) | Mayo Clinic | 2010-11-01 |
| Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma (NCT01460602) | Louisiana State University Health Sciences Center Shreveport | 2010-05-01 |
| Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma (NCT01121757) | Duke University | 2010-04-01 |
| Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL (NCT00772668) | University of Miami | 2009-09-25 |
| Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant (NCT00880815) | M.D. Anderson Cancer Center | 2009-02-17 |
| Lenalidomide and R-CHOP in B-cell Lymphoma (NCT00901615) | Lymphoma Study Association | 2009-01-06 |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma (NCT00644189) | Massachusetts General Hospital | 2008-06-01 |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (NCT00801281) | Polish Lymphoma Research Group | 2007-02-01 |
| Gemcitabine for Marginal Zone Lymphoma (NCT00337259) | Asan Medical Center | 2006-06-01 |
| Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma (NCT00453102) | University of Miami | 2006-02-01 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma (NCT01000753) | Children's Oncology Group | 2005-05-30 |